Beperminogene perplasmid

Drug Profile

Beperminogene perplasmid

Alternative Names: AMG 0001 01; AMG-0001; Collategene; Hepatocyte growth factor gene therapy - AnGes MG; HGF Plasmid

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AnGes MG
  • Developer AnGes MG; Osaka University Hospital
  • Class Antiparkinsonians; Gene therapies; Ischaemic heart disorder therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Hepatocyte growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Ischaemic heart disorders; Lymphoedema; Parkinson's disease

Highest Development Phases

  • Phase III Peripheral arterial disorders
  • Phase I/II Lymphoedema
  • No development reported Arteriosclerosis obliterans; Ischaemic heart disorders; Parkinson's disease; Thromboangiitis obliterans

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Arteriosclerosis-obliterans in Japan (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ischaemic-heart-disorders in Japan (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ischaemic-heart-disorders in USA (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top